Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05650567 · ClinicalTrials.gov registry record · Phase 2
Study of M5049 in DM and PM Participants (NEPTUNIA)
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT05650567 is a Phase 2 study that was terminated before completion, run by EMD Serono Research & Development Institute. The registered enrollment target is 40 participants.
The verdict
NCT05650567, a Phase 2 study, was terminated before completion, sponsored by EMD Serono Research & Development Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM) participants for 24 weeks.
Interventions
- DRUG Placebo
- DRUG M5049 high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-01-19 |
| Est. Completion | 2025-06-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05650567
The ClinicalTrials.gov registry entry for NCT05650567 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05650567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05650567 about?
NCT05650567 is a clinical study titled "Study of M5049 in DM and PM Participants (NEPTUNIA)". The purpose of this study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM) participants for 24 weeks.
What is the current status of trial NCT05650567?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2023-01-19. Estimated completion is 2025-06-25.
What interventions are being tested in trial NCT05650567?
The interventions under investigation include: Placebo (DRUG), M5049 high dose (DRUG).
Who is sponsoring clinical trial NCT05650567?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.